Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non-Small-Cell Lung Cancer

Bevacizumab in combination with topotecan as a salvage therapy for metastatic non-small-cell lung cancer is well tolerated and is worthy of further investigation.